e year ended December 31, 2006, the Company recognized a
$19.5 million gain upon receipt of a termination fee as a result of the
termination of the support agreement with AnorMED in October 2006, net of
transaction costs of approximately $5.5 million. Transaction costs are
included in selling, general and administrative expenses.
Millennium Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
December 31, December 31,
2007 2006
(in thousands)
Cash, cash equivalents and marketable
securities $891,276 $894,349
Other current assets 142,794 121,305
Property and equipment, net 147,869 153,349
Restricted cash and other assets 37,611 35,500
Goodwill and intangible assets, net 1,516,950 1,547,309
Total assets $2,736,500 $2,751,812
Current liabilities $132,475 $125,948
Current portion of long term debt - 99,571
Other long term liabilities 43,337 56,075
Capital lease obligations, net of
current portion 73,795 75,041
Long term debt, net of current portion 250,000 250,000
Stockholders' equity 2,236,893 2,145,177
Total liabilities and
stockholders' equity $2,736,500 $2,751,812
'/>"/>SOURCE Millennium Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Related biology technology :1.
Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation2.
Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing3.
Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer4.
Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation5.
Life Sciences Leader Joins Millennium Board of Directors6.
Millennium to Webcast Third-Quarter 2007 Financial and Operational Results7.
Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales8.
Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market9.
Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets10.
Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order11.
Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection